COPD-related (Chronic Obstructive Pulmonary Disease) Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol 250/50mcg Versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population.

Trial Profile

COPD-related (Chronic Obstructive Pulmonary Disease) Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol 250/50mcg Versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Cholinergic receptor antagonists; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top